More than half of patients with testicular cancer treated with first-line cisplatin-based chemotherapy in a recent study developed hearing loss (HL) or tinnitus. The findings underscore the need for routine assessment for hearing loss and tinnitus during follow-up of cisplatin-treated survivors, the authors of the study emphasize. "The sudden development of hearing loss can be devastating, and often more consequential than the slow progression of age-related hearing loss," they point out. Administration of specific hearing loss questionnaires should be considered in patients who develop HL or tinnitus. These findings indicate that greater hearing loss was associated with lower odds of better overall health, they noted.
Continue reading...